Other TLR4 antagonists such as TAK-242 and Eritoran have also been examined in clinical trials for sepsis/inflammation as reviewed in [40] and may be suitable for ovarian cancer patients overexpressing TLR4 or MyD88. Here, TLR4 is linked to ovarian carcinoma.